CO4940407A1 - Granulos entericos de fluoxetina - Google Patents

Granulos entericos de fluoxetina

Info

Publication number
CO4940407A1
CO4940407A1 CO98026349A CO98026349A CO4940407A1 CO 4940407 A1 CO4940407 A1 CO 4940407A1 CO 98026349 A CO98026349 A CO 98026349A CO 98026349 A CO98026349 A CO 98026349A CO 4940407 A1 CO4940407 A1 CO 4940407A1
Authority
CO
Colombia
Prior art keywords
fluoxetine
enteric
granules
pharmaceutically acceptable
acceptable excipients
Prior art date
Application number
CO98026349A
Other languages
English (en)
Inventor
Robert Anderson Neil
Roger Garrick Harrison
Lynch Daniel Frederick
Peter Lloyd Oren
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940407(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4940407A1 publication Critical patent/CO4940407A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un gránulo entérico de fluoxetina que comprende a) un núcleo compuesto de fluoxetina y uno o más excipientes farmacéuticamente aceptables; b) una capa de separación opcional; c) una capa entérica que comprende succinato acetato de hidroxipropilmetilcelulosa (HPMCAS) y uno o más excipientes farmacéuticamente aceptables; y d) una capa de terminación opcional.
CO98026349A 1997-05-29 1998-05-12 Granulos entericos de fluoxetina CO4940407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (1)

Publication Number Publication Date
CO4940407A1 true CO4940407A1 (es) 2000-07-24

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98026349A CO4940407A1 (es) 1997-05-29 1998-05-12 Granulos entericos de fluoxetina

Country Status (45)

Country Link
US (3) US5910319A (es)
JP (1) JP3210288B2 (es)
KR (1) KR100549473B1 (es)
CN (2) CN1161109C (es)
AR (1) AR011728A1 (es)
AT (1) AT408068B (es)
AU (1) AU726690B2 (es)
BE (1) BE1011925A3 (es)
BR (1) BR9801989A (es)
CA (1) CA2234826C (es)
CH (1) CH693018A5 (es)
CO (1) CO4940407A1 (es)
CZ (1) CZ290582B6 (es)
DE (1) DE19823940B4 (es)
DK (1) DK176776B1 (es)
ES (1) ES2161574B1 (es)
FI (1) FI119971B (es)
FR (1) FR2763846B1 (es)
GB (1) GB2325623B (es)
GR (1) GR980100188A (es)
HU (1) HUP9800882A3 (es)
ID (1) ID20343A (es)
IL (1) IL124073A (es)
IT (1) ITMI980908A1 (es)
LT (1) LT4477B (es)
LU (1) LU90245B1 (es)
LV (1) LV12176B (es)
MY (1) MY118139A (es)
NL (1) NL1009259C2 (es)
NO (1) NO317743B1 (es)
NZ (1) NZ330192A (es)
PE (1) PE75399A1 (es)
PL (1) PL192293B1 (es)
PT (1) PT102152B (es)
RO (1) RO120043B1 (es)
RS (1) RS49827B (es)
RU (1) RU2164405C2 (es)
SE (1) SE522914C2 (es)
SG (1) SG72805A1 (es)
SI (1) SI9800128B (es)
SV (1) SV1998000052A (es)
TR (1) TR199800937A2 (es)
TW (1) TWI239838B (es)
UA (1) UA48193C2 (es)
ZA (1) ZA983173B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
RU2275191C2 (ru) * 1999-05-20 2006-04-27 Элан Корпорейшн, Плс Состоящие из множества частиц фармацевтические составы с контролируемым высвобождением избирательного ингибитора повторного поглощения серотонина
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
IL148159A0 (en) 1999-09-03 2002-09-12 Lilly Co Eli Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058228A1 (en) * 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
BRPI0410840A (pt) 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
JP2007517038A (ja) * 2003-12-30 2007-06-28 ドクター レディズ ラボラトリーズ リミテッド 薬学的組成物
AU2005237360B2 (en) * 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
EP1948599A1 (en) 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
EP2068837A2 (en) * 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
DK2317852T3 (en) 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands
JPWO2010026993A1 (ja) * 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
US20120207825A1 (en) * 2009-09-17 2012-08-16 Sunilendu Bhushan Roy Pharmaceutical compositions for reducing alcohol-induced dose dumping
EP2540318B1 (en) * 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
RU2442572C1 (ru) * 2010-12-23 2012-02-20 Ольга Львовна Титова Энтеросолюбильная оболочка и композиция для ее получения
WO2013164121A1 (en) 2012-05-02 2013-11-07 Capsugel France SAS Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
WO2014034929A1 (ja) 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2015179072A1 (en) 2014-05-20 2015-11-26 Dow Global Technologies Llc Dispersion comprising a partially neutralized esterified cellulose ether
JP6190080B2 (ja) * 2014-05-20 2017-08-30 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルを含むカプセル殻
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
AU2018250628A1 (en) * 2017-04-13 2019-12-05 Chase Therapeutics Corporation Pharmaceutical combination and its use for treating synucleinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP7606825B2 (ja) * 2020-06-15 2024-12-26 東和薬品株式会社 エソメプラゾール顆粒ならびにその製造方法および用途
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
WO1992013452A1 (en) * 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
EP0720478A1 (en) * 1991-05-07 1996-07-10 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
EP0632720B1 (en) * 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE69426570T2 (de) * 1993-11-03 2001-08-23 Isomed, Inc. Mizelleförmige feinteilige pharmazeutische zusammensetzungen
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
LT98058A (en) 1998-10-26
NO982197D0 (no) 1998-05-14
PL326134A1 (en) 1998-12-07
RU2164405C2 (ru) 2001-03-27
LT4477B (lt) 1999-03-25
AT408068B (de) 2001-08-27
FI980846L (fi) 1998-11-30
LV12176B (lv) 1999-03-20
ZA983173B (en) 1999-10-15
ES2161574A1 (es) 2001-12-01
TR199800937A3 (tr) 1999-10-21
LU90245B1 (fr) 2002-07-31
SG72805A1 (en) 2000-05-23
AU726690B2 (en) 2000-11-16
USRE39030E1 (en) 2006-03-21
LV12176A (lv) 1998-12-20
DE19823940A1 (de) 1998-12-03
JPH10330253A (ja) 1998-12-15
GR980100188A (el) 1999-01-29
CN1161109C (zh) 2004-08-11
SV1998000052A (es) 1999-03-16
AU6904898A (en) 1998-12-03
HU9800882D0 (en) 1998-05-28
GB2325623B (en) 1999-04-14
SE9801336D0 (sv) 1998-04-17
GB9807939D0 (en) 1998-06-10
MY118139A (en) 2004-09-30
DK176776B1 (da) 2009-08-10
BR9801989A (pt) 2000-02-08
JP3210288B2 (ja) 2001-09-17
NZ330192A (en) 1999-08-30
NL1009259C2 (nl) 1998-12-01
BE1011925A3 (fr) 2000-03-07
IL124073A (en) 2002-02-10
HUP9800882A3 (en) 2000-07-28
CN1285189A (zh) 2001-02-28
CA2234826A1 (en) 1998-11-29
CN1212834C (zh) 2005-08-03
SE522914C2 (sv) 2004-03-16
US5985322A (en) 1999-11-16
YU16598A (en) 1999-11-22
UA48193C2 (uk) 2002-08-15
NO317743B1 (no) 2004-12-13
NO982197L (no) 1998-11-30
LU90245A1 (es) 1998-11-30
TWI239838B (en) 2005-09-21
GB2325623A (en) 1998-12-02
AR011728A1 (es) 2000-08-30
SI9800128B (sl) 2000-04-30
FI980846A0 (fi) 1998-04-16
CN1200924A (zh) 1998-12-09
TR199800937A2 (xx) 1999-10-21
CZ114398A3 (cs) 1998-12-16
ITMI980908A1 (it) 1999-10-28
ID20343A (id) 1998-12-03
HK1034902A1 (en) 2001-11-09
IE980284A1 (en) 2000-07-12
HUP9800882A2 (hu) 2000-03-28
FR2763846A1 (fr) 1998-12-04
FI119971B (fi) 2009-05-29
CZ290582B6 (cs) 2002-08-14
PT102152B (pt) 2000-09-29
DE19823940B4 (de) 2010-04-29
US5910319A (en) 1999-06-08
RO120043B1 (ro) 2005-08-30
KR100549473B1 (ko) 2006-03-23
KR19980086622A (ko) 1998-12-05
CH693018A5 (de) 2003-01-31
RS49827B (sr) 2008-08-07
SI9800128A (sl) 1999-02-28
PT102152A (pt) 1998-12-31
FR2763846B1 (fr) 2001-05-18
ES2161574B1 (es) 2002-06-16
SE9801336L (sv) 1998-11-30
ATA93198A (de) 2001-01-15
PL192293B1 (pl) 2006-09-29
PE75399A1 (es) 1999-08-17
CA2234826C (en) 2000-12-19

Similar Documents

Publication Publication Date Title
CO4940407A1 (es) Granulos entericos de fluoxetina
YU48095A (sh) Enteričke granule duloksetina
NO20001371L (no) Farmasøytiske preparater inneholdende plasmaprotein
FI973244A7 (fi) Farmaseuttisia valmisteita nenänsisäiseen käyttöön
NO20015797D0 (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
DE69829077D1 (de) Gasentladungsröhre
NO984107L (no) Kappa-agonist-forbindelser og farmas°ytiske preparater derav
NO20001153D0 (no) Etablering av punktstrÕler, sektorer og pikoceller i et kommunikasjonssystem
EE03855B1 (et) Alfusosiinhüdrokloriidi reguleeritult vabastav tablett
DK0794316T3 (da) Packer til brug i en underjordisk brönd
IS5465A (is) Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum
PT1196409E (pt) Inibidores da replicacao do virus sincicial respiratorio
DE60033961D1 (de) Verzweigungs- und zurückbefehl
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
NO20011308L (no) Farmasoytisk preparat som inneholder et syklopeptid og et kjemoterapeutisk middel eller en angiogeneseinhibitor
NO20003234L (no) Oralt administrerbare ribavirindoseformer i fast form og fremgangsmÕte for fremstilling av disse
NL1006065A1 (nl) Inlegkruisje voor stringslip.
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
ES2159260B1 (es) Nueva composicion de metanosulfonato de paroxetina
NO20020848D0 (no) Termoplastisk rörlednings-fôringsrör som ikke krever utlufting av ringrommet mellom fôringsröret og vertsröret
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
GB2407601A (en) Expandable tubular element for use in a wellbore
DE69812423D1 (de) Gasentladungsröhre
DE69816484D1 (de) Gasentladungsröhre